Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

Chevallier, Patrice; Chantepie, Sylvain; Huguet, Françoise; Raffoux, Emmanuel; Thomas, Xavier; Leguay, Thibaut; Marchand, Tony; Isnard, F; Charbonnier, Aude; Maury, Sébastien; Gallego-Hernanz, Maria-Pilar; Robillard, Nelly; Guillaume, Thierry; Péterlin, Pierre; Garnier, Alice; Rialland, Fanny; Houérou, Claire Le; Goldenberg, David M.; Wegener, William A.; Bene, M. C.; Dombret, Hervé

doi:10.3324/haematol.2016.159905

Cited by 7 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the multicenter prospective phase II study of Hyper-CVAD combined with Epratuzumab for young r/r CD22 pre-B ALL, almost half of the patients were MRD negative. It is expected to improve the survival of patients if it is used in first-line therapy especially before allogeneic hematopoietic stem cell transplantation because of Epratuzumab's ability to reduce MRD levels (66).…”

Section: Unconjugated Antibodies/antibody-drug Conjugate (Adc)mentioning

confidence: 99%

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer

Shang

Zhou

2019

Front. Oncol.

View full text Add to dashboard Cite

Recently, due to the application of hematopoietic stem cell transplantation and small molecule inhibitor, the survival of acute leukemia is prolonged. However, the 5 year survival rate remains low due to a high incidence of relapse. Immunotherapy is expected to improve the prognosis of patients with relapsed or refractory hematological malignancies because it does not rely on the cytotoxic mechanisms of conventional therapy. In this paper, the advances of immunotherapy in acute leukemia are reviewed from the aspects of Antibody including Unconjugated antibodies, Antibody-drug conjugate and Bispecific antibody, Chimeric Antigen Receptor (CARs), Immune checkpoint, Natural killer cells. The immunological features, mechanisms and limitation in clinic will be described.

show abstract

Section: Unconjugated Antibodies/antibody-drug Conjugate (Adc)mentioning

confidence: 99%

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer

Shang

Zhou

2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Treatment with epratuzumab was assessed in combination with conventional chemotherapy showing its feasibility in children with relapsed CD22-positive ALL. In several clinical trials, majority of patients achieved early responses [58,59].…”

Section: To Bridge the Tumor Cell To The Killermentioning

confidence: 99%

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Barełkowska¹,

Derwich²

2017

Unique Aspects of Anti-Cancer Drug Development

View full text Add to dashboard Cite

The last decade became the renaissance for investigating and exploring the potential role of immunotherapy in pediatric acute leukemia (AL). It is beyond question that there is an interaction between innate immune system and hematological malignancy. Leukemia cells inhibit the host immune response according to multiple mechanisms, but exploiting the innate immune system mechanisms can overcome the resistance to the conventional treatment. What is the role of immunotherapy in pediatric AL treatment? Does it have the potential to substitute or combine the standard chemotherapy? What is the best possible timing to take advantage of immune interventions? This review is considered to follow through the possible treatment options including their foundation, strong and weak points, but also information about possible implementation into the clinical practice.

show abstract

“…Combining epratuzumab with Hyper-CVAD in very high-risk R/R ALL patients provided an overall response rate of 50%. 36 Almost half of the evaluated responders achieved a negative MRD status. Anti-CD22 fractionated radioimmunotherapy with Yttrium-90 (…”

mentioning

confidence: 99%

Updates in Adult Acute Lymphoblastic Leukemia—Current Status of Antigen-targeted Treatments and Immunotherapy

Thomas¹

2017

Oncology &Amp; Hematology Review (US)

Self Cite

View full text Add to dashboard Cite

T he outcomes of adult acute lymphoblastic leukemia (ALL) remain inferior to those observed in pediatric populations. Targeted therapy with monoclonal antibodies and immunotherapy represents the most promising new way to fight ALL without significant additive toxicity. Since the use of rituximab in combination chemoimmunotherapy for treatment of B cell lineage ALL, a number of other monoclonal antibodies are under investigation for the treatment of this disease. Deep molecular remissions with anti-CD19-and anti-CD22-directed therapy have been shown in relapsed/refractory (R/R) disease, allowing for the opportunity to transplant. Blinatumomab is the first antigen-directed treatment approved for use in R/R ALL. Adoptive cellular therapy with human T cells genetically engineered to express CD19 redirected chimeric antigen receptors (CARs) has also recently demonstrated efficacy in patients with B cell lineage ALL. In this article, we review the therapeutic implications, primary results, and current status of antigen-targeted treatments and immunotherapy in adult B cell lineage ALL. KeywordsAcute lymphoblastic leukemia, monoclonal antibodies, prognosis, blinatumomab, chimeric antigen receptor (CAR) T cells, inotuzumab ozogamicin, rituximab, epratuzumab Disclosure: Xavier Thomas has nothing to declare in relation to this article. No funding was received in the publication of this article. Compliance with Ethics:This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. One approach to improving outcomes in adult ALL involves intensification of existing chemotherapy combinations or the addition of chemotherapeutic agents. 2 The results of allogeneic hematopoietic stem cell transplantation (HSCT) for adults with ALL in first-line therapy have also improved significantly over time, 3 but it is unlikely that the sole intensification of regimens can continue to improve prognosis substantially. Intensifying chemotherapy may reduce the incidence of resistance, but at the cost of increased toxicities. Outcomes remain particularly poor in relapsed/refractory (R/R) patients. Response rates after salvage treatment range from 18-45% and median survival times from 2-8 months, with less than 10% survival after 5 years. [4][5][6][7][8][9] In this setting, allogeneic HSCT is the only curative option, but this can only be achieved in a subgroup of patients. 4,5,8 A retrospective analysis of 1,706 adult patients with Philadelphia chromosome-neg...

show abstract

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

Cited by 7 publications

References 13 publications

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Updates in Adult Acute Lymphoblastic Leukemia—Current Status of Antigen-targeted Treatments and Immunotherapy

Contact Info

Product

Resources

About